Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 561 to 570 of 656 total matches.
Comparison Table: Some Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
relationship has not been
established
▶ Increases oxalate absorption and may
increase the risk of developing ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30 doi:10.58347/tml.2025.1734b | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
clinician;
the equianalgesic dose of methadone is not well established
in opioid-tolerant patients ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
-approved
for treatment of the disorder.2
TREATMENT GOALS — Establishing specific goals
before starting ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
. Whether
ospemifene is safe for use in women with or at risk
for breast cancer remains to be established ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Three New Drugs for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
safety of using them concurrently has not been established. Cholestyramine and presumably colestipol ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Drug Interactions with Grapefruit Juice
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004 (Issue 1173)
; clinical importance not established
Itraconazole (Sporanox) Possible decreased effect Avoid concurrent use ...
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Palladone for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
was established by an unpublished 4week, randomized, double-blind trial in 221 patients
with chronic moderate ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Sildenafil (Revatio) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
with the other therapies for this condition remains to
be established.
1. Sildenafil for pulmonary hypertension. Med Lett ...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006 (Issue 1226)
the prevalence of pertussis and prevent infection
of unvaccinated children remains to be established.
1 ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Abatacept (Orencia) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006 (Issue 1229)
established
rheumatoid arthritis: results from the AIM trial [presentation
1494]. Annual meeting ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).